Aarti Drugs has received Establishment Inspection Report (EIR) from USFDA concluding the inspection as closed for its API manufacturing facility located at Plot No-E-22, MIDC, Tarapur, Maharashtra.UFDA has determined that the inspection classification of this facility is �voluntary action indicated� (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).Powered by Capital Market - Live News

Net profit of Aarti Drugs declined 11.57% to Rs 35.01 crore in the quarter ended September 2024 as against Rs 39.59 crore during the previous quarter ended September 2023. Sales declined 6.74% to Rs 598.33 crore in the quarter ended September 2024 as against Rs 641.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales598.33641.54 -7 OPM %11.2111.92 - PBDT59.6068.88 -13 PBT45.8856.27 -18 NP35.0139.59 -12 Powered by Capital Market - Live News

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live News

Aarti Drugs announced that the bidding process of buyback offer will remain open on Monday, 16 September 2024 (SEBI working day) and close tender offer on Thursday, 19 September 2024 (except Wednesday, 18 September 2024, being holiday). Powered by Capital Market - Live News

Aarti Drugs announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live News